obesity
10 stories tagged "obesity"
Orforglipron Reaches Deep Into the Brain's Reward Circuit and Turns the Dopamine Down
In mice engineered with human GLP-1 receptors, the new oral pills reached the central amygdala, a deep reward hub, and thinned the dopamine payoff of eating for pleasure. The government's addiction institute is already watching.
Metabolic & WeightBoth Groups Lost the Same Seven Kilos. Only the Calorie Counters Had to White-Knuckle It.
In an 18-month Adelaide trial, fasting and daily calorie-cutting stripped off the same seven kilos, but for the counters part of that loss ran on constant conscious restraint the fasters' scores never showed.
Metabolic & WeightSwitch Off One Protein Called Mitch, and Cells Start Eating Their Own Fat
Women with obesity carry more of it. Disable it in mice and they turn lean and muscular at once, the opposite of what the injectable weight-loss drugs do to your body.
Metabolic & WeightObesity Stopped Denting Older Adults' Metabolic Numbers: In the Young It's Biting Harder Than Ever
For middle-aged and older adults, extra weight no longer tracks with the cardiovascular damage it once did. For the young, the same fat is biting harder and earlier. The lab panels converged; the fat didn't.
Metabolic & WeightSame Calories, Different Wiring: Why Fructose Leaves Your Hunger Neurons Running
Glucose flips off the brain cells that drive hunger. Fructose barely nudges them, and the corn-syrup blend in your soda quiets them even better, which is exactly why it's so easy to keep drinking.
Metabolic & WeightThe Belly Fat You Gain After 40 Comes From a Cell That Barely Existed in Your Twenties
Transplant old fat stem cells into a young mouse and they keep churning out fat; young ones in an old mouse stay quiet. In mice, the fat-making program travels with the cell, not the body around it.
Metabolic & WeightThe Obesity 'Revolution' Everyone's Promising Comes From People Who'd Cash In On It
A new commentary says the GLP-1 era is just the prelude to a bigger obesity "revolution." The authors have direct financial stakes in what comes next, and the celebrated new pill loses less weight than the shot.
Metabolic & WeightLilly's triple agonist hit 30% weight loss. The glucagon bet is why.
Lilly's triple agonist hit nearly 30% weight loss at 104 weeks at ADA 2026. The glucagon bet is what makes retatrutide different from semaglutide and Mounjaro, and it's what makes the open safety signals different too.
Metabolic & WeightRetatrutide's Triple-Receptor Triumph Came With a One-in-Five Skin-Sensation Signal Nobody Wanted to Linger On
Eli Lilly's investigational retatrutide hit bariatric-surgery-level weight loss at ADA 2026. The highest-dose arm of TRIUMPH-4 also saw 20.9% of patients report abnormal skin sensations, and a small cardiac imbalance turned up in the type-2 trial. Both got far less stage time than the headline numbe
Metabolic & WeightThe Oral GLP-1 Race Just Got a Third Serious Contender, and Its Curve Was Still Climbing
Structure Therapeutics' once-daily oral GLP-1 aleniglipron hit 11.3 percent placebo-adjusted weight loss at 36 weeks and kept climbing in the open label. The catch: oral semaglutide and orforglipron already cleared the FDA.